FDA Public Health Advisory Recommends Limited Use Of All NSAIDs
This article was originally published in The Tan Sheet
Executive Summary
FDA is recommending "strict accordance" with OTC labeling for all non-selective NSAIDs as part of a public health advisory issued Dec. 23
You may also be interested in...
FDA Advisors Will Give Gut Reaction On COX-2s In Three-Day Meeting
FDA's Arthritis Drugs and Drug Safety & Risk Management advisory committees will discuss the gastrointestinal safety and cardiovascular side effects of COX-2 inhibitors at their February joint meeting
FDA Advisors Will Give Gut Reaction On COX-2s In Three-Day Meeting
FDA's Arthritis Drugs and Drug Safety & Risk Management advisory committees will discuss the gastrointestinal safety and cardiovascular side effects of COX-2 inhibitors at their February joint meeting
FDA Advisors Will Give Gut Reaction On COX-2s In Three-Day Meeting
FDA's Arthritis Drugs and Drug Safety & Risk Management advisory committees will discuss the gastrointestinal safety and cardiovascular side effects of COX-2 inhibitors at their February joint meeting